Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Change in Cash (2018 - 2025)

Historic Change in Cash for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$180097.0.

  • BioNexus Gene Lab's Change in Cash rose 8611.28% to -$180097.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year increase of 6242.3%. This contributed to the annual value of -$1.6 million for FY2024, which is 16798.04% down from last year.
  • BioNexus Gene Lab's Change in Cash amounted to -$180097.0 in Q3 2025, which was up 8611.28% from -$552249.0 recorded in Q2 2025.
  • BioNexus Gene Lab's Change in Cash's 5-year high stood at $4.4 million during Q3 2023, with a 5-year trough of -$1.6 million in Q4 2023.
  • In the last 5 years, BioNexus Gene Lab's Change in Cash had a median value of -$279597.0 in 2022 and averaged -$75294.7.
  • Per our database at Business Quant, BioNexus Gene Lab's Change in Cash surged by 56389.42% in 2022 and then plummeted by 90932.47% in 2025.
  • BioNexus Gene Lab's Change in Cash (Quarter) stood at $423523.0 in 2021, then tumbled by 257.42% to -$666705.0 in 2022, then plummeted by 144.36% to -$1.6 million in 2023, then soared by 113.6% to $221617.0 in 2024, then crashed by 181.26% to -$180097.0 in 2025.
  • Its Change in Cash stands at -$180097.0 for Q3 2025, versus -$552249.0 for Q2 2025 and -$797528.0 for Q1 2025.